Ovation ScienceOVATF 3-Year ROIIC % is 83.46 as of Dec. 2025, which is 78% above its 10-year median of 46.85. The stock has 4 warning signs investors should review. Among 942 Drug Manufacturers companies, Ovation Science ranks better than 88.11% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Ovation Science's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 83.46%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Ovation Science's 3-Year ROIIC % or its related term are showing as below:
OVATF's 3-Year ROIIC % is ranked better than 88.11% of 942
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs OVATF: 83.46
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Ovation Science 3-Year ROIIC % Related Terms
Ovation Science 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Ovation Science's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ovation Science's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ovation Science 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ovation Science's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Ovation Science's 3-Year ROIIC % falls into.
Ovation Science's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.42 (Dec. 2025) - -0.583 (Dec. 2022) )
/
( 0.205 (Dec. 2025) - 0.021 (Dec. 2022) )
=
0.163
/
0.184
=
88.59%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Ovation Science (OVATF) has a 3-Year ROIIC % of 83.46 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Ovation Science and its competitors. This is 78% above median its historical median of 46.85. According to the industry distribution chart, Ovation Science ranks #112 out of 942 companies in the Drug Manufacturers industry, placing it in the top 11.9%.
Is Ovation Science's 3-Year ROIIC % too high?
Ovation Science's current 3-Year ROIIC % of 83.46 is 78% above median its 10-year median of 46.85. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Ovation Science's value of 83.46 is 2143.5% above this industry median. Based on the distribution chart, Ovation Science ranks #112 out of 942 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Ovation Science's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ovation Science ranks #112 out of 942 companies for 3-Year ROIIC %. This places Ovation Science in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.72. Ovation Science's value of 83.46 is 2143.5% above this benchmark. While the company's 10-year median is 46.85 vs. the industry median of 3.72, Ovation Science has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ovation Science's current 3-Year ROIIC % of 83.46 is 2143.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Ovation Science and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovation Science's current 3-Year ROIIC % is 83.46, which is 78% above median its own 10-year median of 46.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovation Science stock overvalued right now?
Ovation Science (OVATF) has a current 3-Year ROIIC % of 83.46. The stock's GF Value™ is $0.05, compared to a current price of $0.04 — trading 30% below its estimated fair value. The current 3-Year ROIIC % is 83.46, which is 78% above median its 10-year median of 46.85 and 2143.5% above the Drug Manufacturers industry median of 3.72. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Ovation Science (OVATF), the current 3-Year ROIIC % is 83.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ovation Science Inc. is a Canada-based company mainly engaged in the business of providing topical and transdermal cannabis products under the Ovation brand label, utilizing patented Invisicare delivery technology. The Company operates in one reportable operating segment, the sub-licensing and sales of cannabis products that utilize Invisicare, a patented polymer-based technology for topical and transdermal skin care products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OVATF has been successfully added to your 